Monte Rosa Therapeutics (GLUE) News Today

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) major shareholder Versant Venture Capital Vi, L. sold 9,269 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $6.16, for a total transaction of $57,097.04. Following the completion of the transaction, the insider now owns 6,231,902 shares of the company's stock, valued at $38,388,516.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Wedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Monte Rosa Therapeutics in a report on Thursday.

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 3.3%

Wells Fargo & Company reduced their price objective on Monte Rosa Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Monday.

Price T Rowe Associates Inc. MD lifted its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 3.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,096,787 shares of the

Piper Sandler reiterated an "overweight" rating and issued a $16.00 price target on shares of Monte Rosa Therapeutics in a report on Friday.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Research analysts at Wedbush lifted their Q2 2024 earnings estimates for shares of Monte Rosa Therapeutics in a research report issued on Tuesday, May 21st. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.37) p

Wedbush restated an "outperform" rating and issued a $11.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,870,000 shares, a growth of 11.3% from the March 31st total of 1,680,000 shares. Based on an average daily volume of 131,800 shares, the days-to-cover ratio is presently 14.2 days. Currently, 5.9% of the shares of the stock are sold short.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 1,840,000 shares, a decline of 7.1% from the February 14th total of 1,980,000 shares. Based on an average daily volume of 191,000 shares, the short-interest ratio is currently 9.6 days. Approximately 5.8% of the company's shares are sold short.